Loading...
•
Mar 31, 2024
RAPT Q1 2024 Earnings Report
Reported financial results for Q1 2024 and announced the decision to close and unblind both the Phase 2b clinical trial of zelnecirnon in atopic dermatitis and the Phase 2a trial of zelnecirnon in asthma.
Key Takeaways
RAPT Therapeutics reported a net loss of $30.5 million for the first quarter of 2024, compared to a net loss of $29.3 million for the first quarter of 2023. The company's cash and cash equivalents and marketable securities totaled $141.6 million as of March 31, 2024. The company also announced the closure of its Phase 2b clinical trial of zelnecirnon in atopic dermatitis and its Phase 2a trial of zelnecirnon in asthma.
Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023.
Research and development expenses for the first quarter of 2024 were $24.8 million, compared to $25.6 million for the same period in 2023.
General and administrative expenses for the first quarter of 2024 were $7.7 million, compared to $6.0 million for the same period in 2023.
As of March 31, 2024, the Company had cash and cash equivalents and marketable securities of $141.6 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...